(Q34319729)

1 August 2017

1 reference

title

Comparison of angiotensin II receptor antagonists (English)

1 reference

1 August 2017

Kirch W

1

1 reference

1 August 2017

Horn B

series ordinal

2

1 reference

1 August 2017

Schweizer J

series ordinal

3

1 reference

1 August 2017

publication date

1 August 2001

1 reference

European Journal of Clinical Investigation

1 August 2017

published in

1 reference

1 August 2017

volume

31

1 reference

1 August 2017

issue

8

1 reference

1 August 2017

page(s)

698-706

1 reference

Angiotensin II receptor antagonists

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2001.00871.X

Angiotensin receptor antagonists: focus on losartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2001.00871.X

Angiotensin II type 2 receptor is upregulated in human heart with interstitial fibrosis, and cardiac fibroblasts are the major cell type for its expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2001.00871.X

Angiotensin II stimulation in vitro induces hypertrophy of normal and postinfarcted ventricular myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2001.00871.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2001.00871.X

In vivo relationship between insulin and endothelin role of insulin-resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2001.00871.X

Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2001.00871.X

A population-based survey of drug treatment efficacy by the French National Committee for the Control of Arterial Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2001.00871.X

Cough and angiotensin II receptor antagonists: cause or confounding?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2001.00871.X

Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2001.00871.X

Mechanisms by which the Hawksley random zero sphygmomanometer underestimates blood pressure and produces a non-random distribution of RZ values.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2001.00871.X

The ELITE Study. What are its implications for the drug treatment of heart failure? Evaluation of Losartan in the Elderly Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2001.00871.X

10.1046/J.1365-2362.2001.00871.X

21 January 2018

Identifiers

DOI

1 reference

1 August 2017

1 reference